Relugolix, also known as MYFEMBREE, has an adapted target of ER GnRHR PR SIRPα. It can be used to treat patients with heavy menstrual bleeding associated with uterine leiomyoma and patients with moderate to severe pain associated with endometriosis, with good clinical effects.

What is the dosage of Relugolix?

Correct medication is the basis for ensuring the therapeutic effect. What is the dosage of Relugolix? Let us learn about it together below.

Recommended dosage

The dosage of Relugolix is one tablet per day, taken at the same time, to maintain the blood concentration of the drug in the body, which can ensure the therapeutic effect of the drug.

How to take Relugolix

Relugolix can be taken before or after meals. Exposure to Relugolix in early pregnancy may increase the risk of early miscarriage, so pay attention to exclude pregnancy before taking the medicine and stop using hormonal contraceptives.

Start taking Relugolix as soon as possible after the start of menstruation, but no later than seven days after the start of menstruation. It is important to avoid using Relugolix with oral P-gp inhibitors. If it is unavoidable to use them at the same time, take Relugolix first and then use P-gp inhibitors at least 6 hours later to avoid drug interactions that affect health.

What to do if you miss a dose

If you miss a dose of Relugolix due to accidental negligence, take the missed dose of Relugolix as soon as possible on the same day, and then resume regular dosing at the normal time of the next day.

Each patient has a different tolerance to Relugolix. If you feel uncomfortable during medication, you should consult a doctor in time and adjust the dose under the guidance of the doctor. Do not blindly adjust the medication on your own. In addition to paying attention to the way of taking the medicine, what other precautions should be taken for the use of Relugolix?

Precautions for the use of Relugolix

Bone loss

Relugolix may cause bone loss. The impact of reduced bone density on long-term bone health and future fracture risk in premenopausal women is still unclear, so Relugolix is contraindicated for women with known osteoporosis. The benefits and risks of Relugolix treatment for patients with a history of low-trauma fractures or risk factors for osteoporosis or bone loss should be considered before taking the medicine. If the medicine is necessary, it should be monitored during the medication.

Hormone-sensitive malignancies

Relugolix has the risk of causing hormone-sensitive malignancies and is contraindicated for women who currently have or have a history of hormone-sensitive malignancies (such as cancer) and women with increased risk of hormone-sensitive malignant diseases. If a hormone-sensitive malignancy is diagnosed, stop using Relugolix under the guidance of a doctor.

During the use of Relugolix, you should pay attention to nutrition and a balanced diet, and you should also go to the hospital for regular checkups according to the doctor's treatment plan to understand your own recovery.